The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review
Open accessAbstract
Diabetes mellitus is a chronic disease characterized by high social, economic and health burden, mostly due to the high incidence and morbidity of diabetes complications. Numerous studies have shown that optimizing metabolic control may reduce the risk of micro and macrovascular complications related to the disease, and the algorithms suggest that an appropriate and timely step of care intensification should be proposed after 3 months from the failure to achieve metabolic goals. Nonetheless, many population studies show that glycemic control in diabetic patients is often inadequate. The phenomenon of clinical inertia in diabetology, defined as the failure to start a therapy or its intensification/de-intensification when appropriate, has been studied for almost 20 years, and it is not limited to diabetes care, but also affects other specialties. In the present manuscript, we have documented the issue of inertia in its complexity, assessing its dimensions, its epidemiological weight, and its burden over the effectiveness of care. Our main goal is the identification of the causes of clinical inertia in diabetology, and the quantification of its social and health-related consequences through the adoption of appropriate indicators, in an effort to advance possible solutions and proposals to fight and possibly overcome clinical inertia, thus improving health outcomes and quality of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the patient level, concerns over drug side effects, misunderstanding the different treatment regimens, comorbidities, terminal illnesses, trypanophobia, a limited doctor–patient relationship, low education level, and socioeconomic status are major barriers for therapeutic intensification [10].”
From Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In terms of optimal management of diabetes, clinical inertia is a remarkable barrier to therapeutic success, because it delays the intensification of treatment [10].”
From Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review (2023) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In about 30% of the individuals, IGT or impaired fasting glucose (IFG) progresses to diabetes.”
From Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review (2023) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2011) · Cited by 14,317
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Research works printed but not linked: 3
- Annals of AMD 2018. Assessment of AMD diabetes quality assistence indicators in Italy; 2018. https://aemmedi.it/wp-content/uploads/2019/05/AMD-Monografia-SGLT-2i-web-protetto.pdf. Accessed 27 Sept 2019.
- Monographs of the Annals of AMD 2012. Focus on changes to treatment in type 2 diabetes. 2012. http://www.infodiabetes.it/files/ANNALI-AMD/2013/Annali%202013%20Terapie%20per%20web.pdf. Accessed 5 Nov 2019.
- Pellegrini MA, Ercoli A, Musacchio N, Zilich R, Mannino D. Inerzia terapeutica del Diabetologo: dall’algoritmo clinico all’algoritmo mentale. Progetto DIADEMA-AMD. J AMD. 2019;22:9.
Cited by
Sorted by citations
Artificial intelligence for diabetes care: current and future prospects
Sheng, B., Pushpanathan, K., Guan, Z., Lim, Q. H., Lim, Z. W., Yew, S. M. E., Goh, J. H. L., Bee, Y. M., Sabanayagam, C., Sevdalis, N., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00154-2 · Cited by 106
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease
Nee, R., Yuan, C. M., Narva, A. S., Yan, G., & Norris, K. C. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac283 · Cited by 83
Pereira, L., & Valado, A. (2023) · Life · doi:10.3390/life13091831 · Cited by 59
Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review
Almigbal, T. H., Alzarah, S. A., Aljanoubi, F. A., Alhafez, N. A., Aldawsari, M. R., Alghadeer, Z. Y., & Alrasheed, A. A. (2023) · Medicina · doi:10.3390/medicina59010182 · Cited by 58
“In terms of optimal management of diabetes, clinical inertia is a remarkable barrier to therapeutic success, because it delays the intensification of treatment [10].”
BackgroundInfluentialBain, S. C., Bekker Hansen, B., Hunt, B., Chubb, B., & Valentine, W. J. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2019.1645018 · Cited by 53
Metadata
- Authors
- Andreozzi, F., Candido, R., Corrao, S., Fornengo, R., Giancaterini, A., Ponzani, P., Ponziani, M. C., Tuccinardi, F., & Mannino, D.
- Affiliations
- Magna Graecia University (IT)
- Azienda Sanitaria Universitaria Integrata di Trieste (IT)
- University of Palermo (IT)
- Azienda ospedaliera "Bianchi-Melacrino-Morelli" (IT)
- Corresponding author
- Andreozzi, F.
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2020-06-17
- Volume
- 12
- Issue
- 1
- Pages
- 52-52
- ISSN
- 1758-5996 (ISSN-L)
- PMC
- PMC7301473
- OpenAlex
- W3036158386
- Cited by
- 128
- References
- 89
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 27 · 2023: 25 · 2022: 22 · 2021: 23 · 2020: 2
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- MSD Italia
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- clinical inertia, diabetes mellitus, glycemic control, diabetes complications, microvascular complications, macrovascular complications, treatment intensification, quality of care, health outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
